MR Metformin and SGLT2i Now First-Line in Type 2 Diabetes
The National Institute for Health and Care Excellence (NICE) has revised its guidance to recommend modified-release metformin and SGLT2 inhibitors as the first-line treatment for most individuals with type 2 diabetes. This change is seen as a significant shift in practice, emphasizing a holistic approach to diabetes management that includes cardiovascular and renal health. The updated guidelines reflect the increasing prevalence of type 2 diabetes and the need for effective treatment strategies.
- ▪NICE now recommends modified-release metformin and SGLT2 inhibitors as first-line treatments for type 2 diabetes.
- ▪The update aims to improve patient adherence and reduce gastrointestinal side effects associated with standard metformin.
- ▪The guidance emphasizes a holistic approach to diabetes management, focusing on cardiovascular and renal protection.
Opening excerpt (first ~120 words) tap to expand
BIRMINGHAM, UK — Modified-release (MR) metformin and a sodium-glucose cotransporter-2 inhibitor (SGLT2i) should be the first line of treatment for most people with type 2 diabetes according to revised guidance from the National Institute for Health and Care Excellence (NICE), it was reported at the Primary Care Show. This was a “game-changer” for practice, said Roy Hamilton, a GP senior partner with a specialist interest in diabetes and cardiovascular-renal-metabolic (CVRM) medicine who is based in Worcester. Metformin has been the standard of care for years, often in combination with a sulphonylurea, so it was, he said, “practice changing” to not only recommend the MR formulation over standard release but to then add in an SGLT2i.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
